Home  »  Equity Investing   »  Here’s What you Should Know About Rising Premark...

Here’s What you Should Know About Rising Premarket Genprex, Inc. (GNPX) Stock

Genprex, Inc. (GNPX) is a leading clinical-stage biopharmaceutical company. The company is engaged in the development of disease-fighting genes for the treatment of cancer and diabetes patients. One of the company’s lead drug candidates is REQORSA being assessed for the treatment of non-small cell lung cancer. The company is also developing GPX-002 as the genetic therapy method for diabetes. Another product candidate is ONCOPREX which is a nanoparticles delivery platform.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


The price of GNPX stock during the regular trading on January 6, 2022, was $2.21 with a 2.64% drop. At last check in the premarket on January 7, 2022, the stock surged by 5.88%.

GNPX: Events and Happenings

On January 5, 2022, GNPX reported that the company’s Executives will participate in the following investor and healthcare conferences. Virtual HC Wainwright BIOCONNECT 2022 Conference which will be held on January 10-13, Biotech Showcase 2022 being held on January 10-13, Virtual Precision: Lung Cancer World R&D Summit on 25-26 January, and CEO Roadshow on January 26, 2022.

On January 4, 2022, GNPX reported about the expansion of its research and development pipeline related to cancer for the inclusion of small cell lung cancer as an extra disease indication for REQORSA. SCLC represented up to 10-15% of the lung cancer portfolio, whereas REQORSA’s preliminary target indication of NSCLC represented up to 84% of the lung cancer portfolio.

On January 3, 2022, GNPX reported about the grant of Fast Track Designation by FDA for its lead product REQORSA, along with Keytruda of Merck & Company. The company expected to start its Acclaim-2 clinical trial. Earlier, GNPX received its initial FTD for REQORSA along with Tagrisso of AstraZeneca PLC.

GNPX: Key Financials

On November 15, 2021, GNPX reported its financial results for the third quarter ended September 30, 2021. Some of the important highlights are as follows.

Net Loss per Share

Basic and diluted net loss per share for the third quarter of 2021 was $3.4 million or $0.07 per share as compared to the net loss for the same period of 2020 when it was $2.7 million or $0.07 per share.

Total Current Assets

Total current assets reported for the company for Q3 2021 were $45.6 million.


GNPX stock is 47% up to as compared to the last month. Although the stock tumbled in the regular trading it bounced back in the current premarket session. The surge in stock price is possibly associated with the company’s announcement regarding its participation in investor and healthcare conferences. The analysts are optimistic that the company will maintain its current track record and will attract potential investors in the future.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts